コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nfavorable prognosis of PAX3-FOXO1 fusion in alveolar rhabdomyosarcoma.
2 man myogenesis and the muscle-related cancer alveolar rhabdomyosarcoma.
3 nhibitors holds promise for the treatment of alveolar rhabdomyosarcoma.
4 adiosensitizer for the clinical treatment of alveolar rhabdomyosarcoma.
5 dismal prognosis for invasive or metastatic alveolar rhabdomyosarcoma.
6 IR) is an essential component of therapy for alveolar rhabdomyosarcoma.
7 e use of fusion gene status to risk stratify alveolar rhabdomyosarcoma.
8 binding sites and associated target genes in alveolar rhabdomyosarcoma.
9 n gene is associated with the development of alveolar rhabdomyosarcoma.
10 ltured cells from a common pediatric cancer, alveolar rhabdomyosarcoma.
11 cipal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.
12 ate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.
13 al translocation, a unique genetic marker of alveolar rhabdomyosarcoma.
14 1 is frequently found in Ewing's sarcoma and alveolar rhabdomyosarcoma.
15 3) chromosomal translocation associated with alveolar rhabdomyosarcoma.
16 ional organisation of the fused landscape in alveolar rhabdomyosarcoma.
17 al translocation seen in the pediatric tumor alveolar rhabdomyosarcoma.
18 ling, is a downstream target of PAX3-FKHR in alveolar rhabdomyosarcoma.
19 AX3 and FKHR is characteristic of most human alveolar rhabdomyosarcomas.
20 gion was unmethylated in the majority of the alveolar rhabdomyosarcomas (13 of 15, 87%) examined in t
21 scle tumors that resembled the human form of alveolar rhabdomyosarcoma, a cancer associated with poor
22 translocation occurs at a high frequency in alveolar rhabdomyosarcoma, a common pediatric tumor of m
24 13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric
25 ) and t(1;13)(p36;q14) are characteristic of alveolar rhabdomyosarcoma, a pediatric soft tissue cance
26 st that PKCiota is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth a
27 der the receiver operating curve of 0.94 for alveolar rhabdomyosarcoma and an area under the receiver
28 osarcoma cell lines, independent of lineage (alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma
29 s model offers new insight into the roots of alveolar rhabdomyosarcoma and illustrates the utility of
30 The Pax3-FKHR fusion protein is present in alveolar rhabdomyosarcoma and results from the t(2;13) (
33 ogic subtype, with poor outcomes observed in alveolar rhabdomyosarcoma (ARMS) and the adult-type pleo
34 the successful purification of RNA from the alveolar rhabdomyosarcoma (ARMS) cancer cell line, with
35 gene expression profile of a group of seven alveolar rhabdomyosarcoma (ARMS) cell lines characterize
37 tologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival
38 the PAX3-FKHR and PAX7-FKHR gene fusions in alveolar rhabdomyosarcoma (ARMS) indicated that the corr
52 The t(2;13) and t(1;13) translocations of alveolar rhabdomyosarcoma (ARMS) result in chimeric PAX3
53 a mouse model of the childhood muscle cancer alveolar rhabdomyosarcoma (ARMS) that is driven by the c
54 ted by the 2;13 chromosomal translocation in alveolar rhabdomyosarcoma (ARMS), a cancer associated wi
55 muscle development and is a key component in alveolar rhabdomyosarcoma (ARMS), a childhood solid musc
56 To put the concept into use, we selected alveolar rhabdomyosarcoma (ARMS), a myogenic pediatric c
57 1 fusion transcription factor, which induces alveolar rhabdomyosarcoma (aRMS), an aggressive cancer o
59 slocation occurs in most cases of the cancer alveolar rhabdomyosarcoma (ARMS), and juxtaposes the gen
60 he oncogenic fusion TF PAX3-FOXO1 (P3F) from alveolar rhabdomyosarcoma (aRMS), we show that a single
61 s remain dismal for patients with metastatic alveolar rhabdomyosarcoma (aRMS), where the chimeric tra
68 R fusion protein is present in a majority of alveolar rhabdomyosarcomas associated with increased agg
69 l involvement; and those with non-metastatic alveolar rhabdomyosarcoma but without nodal involvement.
70 ormal conditions, while in a patient-derived alveolar rhabdomyosarcoma cell line, harbouring the diag
74 (2;13)(q35;q14) chromosomal translocation in alveolar rhabdomyosarcoma, consists of the two Pax3 DNA
76 The chromosomal translocation that leads to alveolar rhabdomyosarcoma development generates a novel
77 oma includes two histolopathologic subtypes: alveolar rhabdomyosarcoma, driven by the fusion protein
79 nt histologic variants of RMS, embryonal and alveolar rhabdomyosarcoma (eRMS and aRMS, respectively),
81 ater understanding of the means by which the alveolar rhabdomyosarcoma gene fusions (PAX-FKHR) lead t
85 3), Craniofacial-deafness-hand syndrome and alveolar rhabdomyosarcoma in humans and the Splotch phen
86 mary mutations and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immuno
95 observed in 22 of 26 rhabdomyosarcomas, all alveolar rhabdomyosarcomas (nine of nine) showed high le
97 are generally cured, although patients with alveolar rhabdomyosarcoma or undifferentiated sarcoma, p
100 ed to overexpress PAX3-FKHR and PAX7-FKHR in alveolar rhabdomyosarcoma, presumably due to differences
104 immunohistochemical profile similar to human alveolar rhabdomyosarcoma, suggesting that this conditio
105 view, we specifically focus on embryonal and alveolar rhabdomyosarcoma, synovial sarcoma, and adult s
107 suggesting that PAX3-FKHR exerts its role in alveolar rhabdomyosarcomas through dysregulation of PAX3
108 The t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma tumors (ARMS) creates an oncog
109 c translocations (two synovial sarcomas, two alveolar rhabdomyosarcomas, two desmoplastic round cell
111 e translocation-associated gene Pax3:Fkhr in alveolar rhabdomyosarcomas, we generated a Cre-mediated